SP Funds Trust SP Funds S&P Global Technology ETF (ARCA: SPTE)

Dernières nouvelles pour SP Funds Trust SP Funds S&P Global Technology ETF (ARCA:SPTE)

The Fund uses a passive management (or indexing) approach to track the performance, before fees and expenses, of the Index. The S&P Global 1200 Shariah Information Technology Capped Index is designed to measure the performance of global large-cap equity securities within the information technology sector that pass rules-based screens for adherence to Shariah investment guidelines, with a cap applied to ensure diversification among companies in the Index..

Taiwan Semiconductor Manufacturing Co. Ltd. Adr ( Tsm )

Nvidia Corp.

Microsoft Corp

Apple Inc

Asml Holding Nv

Sap S.e., ADR

Broadcom Inc

Tokyo Electron Ltd Unspn Adr

Keyence Corp

Shopify Inc.

SP Funds S&P Global Technology ETF

SP Funds Trust SP Funds S&P Global Technology ETF

Consolidated copper production for 2025 is expected to range between 75,000 to 85,000 tonnes. The Company remains focused on steadily increasing plant throughput and achieving commercial production at the Tucumã Operation in H1 2025.&nbsp;
As a result, copper production is expected to increase sequentially each quarter, with Tucumã expected to contribute significantly to the full-year consolidated copper production.

News

Guidance

Ero Copper Expects 2025 Capital Expenditures To Decrease To Range Of $230M - $270M

Scotiabank analyst Phil Hardie maintains First National Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FN#TSX">FN</a>) with a Sector Perform and raises the price target from C$44 to C$45.

Price Target

Analyst Ratings

TSX:FN

Scotiabank Maintains Sector Perform on First National Financial, Raises Price Target to C$45

Ero Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.31 by 45.16 percent. This is a 19.05 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $122.50 million which missed the analyst consensus estimate of $146.57 million by 16.42 percent. This is a 5.24 percent increase over sales of $116.40 million the same period last year.

Earnings

Earnings Misses

Ero Copper Q4 2024 Adj EPS $0.17 Misses $0.31 Estimate, Sales $122.50M Miss $146.57M Estimate

Scotiabank analyst Holly Stewart maintains Enterprise Prods Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) with a Sector Perform and raises the price target from $33 to $35.

Scotiabank Maintains Sector Perform on Enterprise Prods Partners, Raises Price Target to $35

The maximum number of common shares which may be purchased by Sprott during the NCIB will not exceed 645,333 common shares being approximately 2.5% of 25.81 million (representing the number of issued and outstanding common shares as of February 28, 2025).

Buybacks

Sprott Says TSX Approved Notice Of Intention To Make Normal Course Issuer Bid; Plan Not To Exceed 645,333 Common Shares

A federal judge extended an order on Thursday that prevents <a href="https://www.benzinga.com/topic/donald-trump">the Trump administration</a> from freezing billions in congressionally approved funds to 22 states and the District of Columbia.
The New York Times <a href="https://www.nytimes.com/2025/03/06/us/politics/trump-funding-freeze-states.html">reported</a> that the judge found the administration had overstepped in trying to stop the agencies from using money appropriated by Congress.
Judge John J. McConnell Jr. of the Federal District Court for the District of Rhode Island, said in the opinion that the case amounted to executive overreach.
"Here, the executive put itself above Congress," McConnell wrote. "It imposed a categorical mandate on the spending of congressionally appropriated and obligated funds without regard to Congress's authority to control spending."
What Happened: Thursday&#8217;s injunction, the second ordered by a federal court blocking the spending freeze, marks a victory for Democratic attorneys general who filed suit against the Trump administration over its efforts to slash trillions of dollars in order to evaluate whether the programs in question aligned with the president&#8217;s policy goals.
The White House budget office memo that got the ball rolling last month sent millions of workers across the country into a collective state of confusion and insecurity, after which a coalition of state attorneys general launched lawsuits.
The Judge McConnell&#8217;s order, aimed at all the federal agencies cited in the White House memo, directs them to refrain from "pausing, freezing, blocking, canceling, suspending, terminating or otherwise impeding the disbursement of appropriated federal funds to the States under awarded grants, executed contracts or other executed financial obligations."
While the decision represents a rebuke of the spending freeze, <a href="https://www.npr.org/2025/03/06/nx-s1-5312069/trump-federal-funding-freeze-court-order">noted</a> NPR, the preliminary injunction only applies in the states that brought the challenge.
Nevertheless, the ruling was praised by the attorneys general who filed the lawsuit.
&#8220;Americans should feel encouraged that the President cannot impose his will where he does not have the constitutional power to do so. And while he may continue to try, we will continue to fight,&#8221; Rhode Island&#8217;s Attorney General Peter Neronha said&nbsp;<a href="https://riag.ri.gov/press-releases/attorney-general-neronha-recommits-defending-constitution-following-court-decision" target="_blank" rel="noreferrer noopener">in a statement</a>.
"We don't have kings in this country, and today's preliminary injunction reaffirms that&#8221; he continued. "The President's federal funding freeze would be laughable if it wasn't so utterly destructive. It flies in the face of everything we know to be true about our government, namely our separation of powers, by attempting to render the Congress as irrelevant."
<h2 class="wp-block-heading">Trump-Musk Response?</h2>
​As of now, neither President Donald Trump nor Elon Musk, head of the Department of Government Efficiency (DOGE), has issued an official response to the recent decision. However, Musk <a href="https://x.com/elonmusk/status/1897671125775138945">commented </a>on X (formerly Twitter), stating, &#8220;The Democratic government-funded NGO scam might be the biggest theft of taxpayer money ever.&#8221; ​
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44176918/trump-delays-mexico-tariffs-for-a-month-economic-uncertainty-persits">Trump Delays Mexico Tariffs For A Month, Economic Uncertainty Persists</a></li>
</ul>
Photo: Shutterstock

Politics

Legal

Federal Judge Blocks Trump's Freeze On Billions In Congressional Funds: 'Executive Put Itself Above Congress'

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) reported first-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/03/n44179784/broadcom-inc-announces-first-quarter-fiscal-year-2025-financial-results-and-quarterly-dividend">from the quarter</a>.
Q1 Earnings: Broadcom reported first-quarter revenue of $14.92 billion, beating&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a>&nbsp;of $14.61 billion, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The semiconductor company reported first-quarter adjusted earnings of $1.60 per share, beating analyst estimates of $1.49 per share.
Total revenue was up 25% on a year-over-year basis, driven by strength in AI semiconductor solutions and infrastructure software. Broadcom generated $6.11 billion in cash from operations and $6.01 billion in free cash flow during the quarter. The company ended the quarter with approximately $9.31 billion in cash and cash equivalents.
&#8220;Q1&nbsp;AI revenue grew&nbsp;77%&nbsp;year-over-year to&nbsp;$4.1 billion&nbsp;and infrastructure software revenue grew&nbsp;47%&nbsp;year-over-year to&nbsp;$6.7 billion,&#8221; said&nbsp;Hock Tan, president and CEO of Broadcom.
&#8220;We expect continued strength in AI semiconductor revenue of&nbsp;$4.4 billion&nbsp;in&nbsp;Q2, as hyperscale partners continue to invest in AI XPUs and connectivity solutions for AI data centers.&#8221;
Broadcom&#8217;s board approved a quarterly cash dividend of 59 cents per share, payable on March 31 to shareholders of record as of March 20.
See Also: <a href="https://www.benzinga.com/news/global/25/03/44176918/trump-delays-mexico-tariffs-for-a-month-economic-uncertainty-persits">Trump Delays Mexico Tariffs For A Month, Economic Uncertainty Persists</a>
Outlook: Broadcom expects second-quarter revenue of approximately $14.9 billion, versus estimates of $14.76 billion. The company anticipates first-quarter adjusted EBITDA of approximately 66% of projected revenue.
Broadcom executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
AVGO Price Action: <a href="https://www.benzinga.com/quote/AVGO" target="_blank" rel="noreferrer noopener">Broadcom shares</a> were up 8.73% after hours, trading at $195.11 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

After-Hours Center

Movers

Tech

AVGO

Broadcom Stock Surges On Q1 Earnings Beat, Revenue Beat, Strong Guidance: 'We Expect Continued Strength In AI Semiconductor Revenue'

BRBR

BellRing Brands Board Approves $300M Share Repurchase Authorization Over Next Two Years

Throughout the last three months, 4 analysts have evaluated EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $30.25, with a high estimate of $33.00 and a low estimate of $22.00. This upward trend is apparent, with the current average reflecting a 3.14% increase from the previous average price target of $29.33.
<img src="https://www.benzinga.com/files/images/story/2025/1741298458_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of EyePoint Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$33.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to EyePoint Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EyePoint Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into EyePoint Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EYPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on EyePoint Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into EyePoint Pharmaceuticals's Background</h2>
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
<h3>EyePoint Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, EyePoint Pharmaceuticals faced challenges, resulting in a decline of approximately -30.77% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: EyePoint Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -278.99%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): EyePoint Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of -13.14%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): EyePoint Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.39%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.1, EyePoint Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EYPT

Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews

Discover Financial servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) has outperformed the market over the past 5 years by 9.81% on an annualized basis producing an average annual return of 24.52%. Currently, Discover Financial servs has a market capitalization of $43.44 billion. 
Buying $100 In DFS: If an investor had bought $100 of DFS stock 5 years ago, it would be worth $315.32 today based on a price of $172.67 for DFS at the time of writing.
<h3>Discover Financial servs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741298419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Discover Financial servs 5 Years Ago Would Be Worth Today

Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) with a Buy and maintains $33 price target.

Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $33 Price Target

Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) sees Q1 sales of $33.000 million-$35.000 million vs $35.38 million analyst estimate.

ASUR

Asure Software Sees Q1 Sales $33.000M-$35.000M vs $35.38M Est

Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) affirms FY2025 sales outlook from $134.00 million-$138.00 million to $134.00 million-$138.00 million vs $134.65 million estimate.

Asure Software Affirms FY2025 Sales Guidance of $134.00M-$138.00M vs $134.65M Est

Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $0.18 by 16.67 percent. This is a 87.5 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $30.79 million which missed the analyst consensus estimate of $30.80 million by 0.04 percent. This is a 17.24 percent increase over sales of $26.26 million the same period last year.

Asure Software Q4 Adj EPS $0.15 Misses $0.18 Estimate, Sales $30.79M Miss $30.80M Estimate

The company's outlook is based on its best assessment of the current macroeconomic environment and related headwinds to consumer spending, including, but not limited to, inflationary pressures, tariffs, supply chain disruptions and foreign currency volatility.
 &nbsp;

Gap Expects FY25 Net Sales Growth Of 1% - 2% And Flat To Up Slightly For Q1

Macquarie analyst Paul Golding maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Outperform and maintains $110 price target.

Macquarie Maintains Outperform on Block, Maintains $110 Price Target

BigBear.ai Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) released its fourth-quarter results after Thursday's closing bell. Here's a look at the details <a href="https://www.benzinga.com/pressreleases/25/03/b44179893/bigbear-ai-announces-fourth-quarter-and-full-year-2024-results-and-provides-2025-outlook">from the report. </a>
The Details: BigBear.ai reported quarterly losses of 43 cents per share, which missed the analyst consensus estimate for losses of five cents. Quarterly revenue came in at $43.8 million, which missed the analyst consensus estimate of $54.48 million and is an increase over sales of $40.56 million from the same period last year.
Gross margin was 37.4% in the fourth quarter of 2024 as compared to 32.1% in the fourth quarter of 2023. Ending backlog was $418 million as of Dec. 31, 2024, an increase of $250 million or 2.5 times ending backlog as of Dec. 31, 2023.
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/03/44172028/trade-turmoil-oil-slides-whats-driving-markets-thursday">Trade Turmoil, Oil Slides: What&#8217;s Driving Markets Thursday?</a>&nbsp;
&#8220;2024 was a pivotal year for the business. We demonstrated momentum through major contract wins, expanding our backlog and growing our pipeline, maturing our technology portfolio, and restructuring our debt to strengthen our financial position for the long term. These efforts were driven by strong execution from our team,&#8221; said Kevin McAleenan, CEO of&nbsp;BigBear.ai.
Outlook:&nbsp;The company expects fiscal 2025 revenue in a range of $160 million to $180 million. 
BBAI Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, BigBear.ai shares were down 5.48% after-hours at $3.97 after falling 12.5% in regular trading Thursday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a></li>
</ul>
Photo: Shutterstock

BBAI

BigBear.ai Stock Plummets After Q4 EPS, Revenues Miss: Details

Tigress Financial analyst Ivan Feinseth maintains Travel+Leisure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) with a Buy and raises the price target from $64 to $70.

Tigress Financial Maintains Buy on Travel+Leisure, Raises Price Target to $70

Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) has outperformed the market over the past 15 years by 6.14% on an annualized basis producing an average annual return of 17.41%. Currently, Constellation Brands has a market capitalization of $32.34 billion. 
Buying $100 In STZ: If an investor had bought $100 of STZ stock 15 years ago, it would be worth $1,130.45 today based on a price of $178.95 for STZ at the time of writing.
<h3>Constellation Brands's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741297509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.60 by 33.33 percent. This is a 370.59 percent increase over earnings of $0.17 per share from the same period last year. The company reported $480.90 million in sales this quarter. This is a 6.16 percent increase over sales of $453.00 million the same period last year.

Comments

SP Funds Trust SP Funds S&P Global Technology ETF

Actualités

Dernières nouvelles pour SP Funds Trust SP Funds S&P Global Technology ETF (ARCA:SPTE)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL